AKT1 and type 2 diabetes mellitus: Taraxerol also stimulates the IRS1/PI3K/AKT/AMPK/GLUT4/GSK3β signaling pathways to mediate hyperglycemia and inhibits the PKC/NF-κB signaling pathway to improve inflammatory effects in T2DM rats [72].